Drugs

, Volume 68, Issue 7, pp 925–947

Guide to the Use of Proton Pump Inhibitors in Adult Patients

  • Vandana Boparai
  • Jaishree Rajagopalan
  • George Triadafilopoulos
Review Article

Abstract

Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they effectively alleviate acid-peptic symptoms and facilitate healing of inflamed or ulcerated mucosa. Although the use of PPIs is nowadays short term in patients with Helicobacter pylori-related peptic ulcer disease, these drugs are increasingly used long term, frequently for a lifetime, in patients with typical or atypical symptoms of gastro-oesophageal reflux disease, and in NSAID or aspirin users at risk for gastrotoxicity and related complications, such as bleeding, perforation and gastric outlet obstruction. This review outlines the essentials of PPI pharmacology, the safety and adverse profiles of the various available agents, and balances them against their clinical short- and long-term benefits. PPI use, prophylactically or with a therapeutic intent may also be combined with other strategies, such as endoscopic therapy, surgery or antibacterial use. Various clinical endpoints, such as symptom relief, mucosal healing, prevention of disease recurrence or complications, and cancer chemoprevention, are discussed and unmet needs are highlighted.

References

  1. 1.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118(2 Suppl. 1): S9–31PubMedCrossRefGoogle Scholar
  2. 2.
    De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91(2): 333–7PubMedGoogle Scholar
  3. 3.
    Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13: 611–6PubMedCrossRefGoogle Scholar
  4. 4.
    Williams MP, Sercombe J, Hamilton MI, et al. A placebo controlled trial to assess the effects of 8 days of dosing with rabeprozole versus omeprazole on 24hr intragastric acidity and plasma gastric concentration in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079–89PubMedCrossRefGoogle Scholar
  5. 5.
    Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559–68PubMedCrossRefGoogle Scholar
  6. 6.
    Ip S, Bonis P, Tatsioni A, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: evidence report/technology assessment number 1. Rockville (MD): Agency for Healthcare Research and Quality, 2005 DecGoogle Scholar
  7. 7.
    Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000; 160: 2491–6PubMedCrossRefGoogle Scholar
  8. 8.
    Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955–60PubMedCrossRefGoogle Scholar
  9. 9.
    Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33–8PubMedCrossRefGoogle Scholar
  10. 10.
    Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947–53PubMedCrossRefGoogle Scholar
  11. 11.
    Consumer Reports®. Drugs to treat heartburn, ulcers, and stomach acid reflux: the proton pump inhibitors comparing effectiveness, safety, and price. Available from URL: http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/PPIsUpdate-FINAL.pdf [Accessed 2008 Mar 5]
  12. 12.
    Allgood LD, Grender JM, Shaw MJ, et al. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther 2005; 30: 105–12PubMedCrossRefGoogle Scholar
  13. 13.
    Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20mg on-demand is more acceptable to patients than continuous lansoprazole 15mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study. Aliment Pharmacol Ther 2004; 20: 657–65PubMedCrossRefGoogle Scholar
  14. 14.
    McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005; 3: 553–63PubMedCrossRefGoogle Scholar
  15. 15.
    Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1–16CrossRefGoogle Scholar
  16. 16.
    Klauser AG, Schindlebeck NE, Muller-Lissner SA. Symptoms in gastroesophageal reflux disease. Lancet 1990; 335: 205–8PubMedCrossRefGoogle Scholar
  17. 17.
    Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 20–6PubMedCrossRefGoogle Scholar
  18. 18.
    Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277–95PubMedCrossRefGoogle Scholar
  19. 19.
    Kahrilas PJ. Refractory heartburn. Gastroenterology 2003; 124: 1941–5PubMedCrossRefGoogle Scholar
  20. 20.
    Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–810PubMedCrossRefGoogle Scholar
  21. 21.
    Venebles TL, Newland RD, Patel AC, et al. Omeprazole 10mg once daily, omeprazole 20 milligrams once a daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for relief of symptoms of gastro-esophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965–73CrossRefGoogle Scholar
  22. 22.
    Miner Jr P, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenter 2002; 97: 1332–9PubMedCrossRefGoogle Scholar
  23. 23.
    Johnston BT, McFarland RJ, Collins JS, et al. Symptoms index as a marker of gastro-oesophageal reflux disease. Br J Surg 1992; 79: 1054–5PubMedCrossRefGoogle Scholar
  24. 24.
    Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907–14PubMedCrossRefGoogle Scholar
  25. 25.
    Talley NJ, Lauritsen K, Tunturi-Hihnalas H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54PubMedCrossRefGoogle Scholar
  26. 26.
    Pace F, Torini M, Pallotta S, et al. Systematic review: maintenance treatment of GERD with proton pump inhibitors taken ‘on demand’. Aliment Pharmacol Ther 2007; 26: 195–204PubMedCrossRefGoogle Scholar
  27. 27.
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut 1999; 45: 172–80PubMedCrossRefGoogle Scholar
  28. 28.
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65PubMedCrossRefGoogle Scholar
  29. 29.
    Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249–58CrossRefGoogle Scholar
  30. 30.
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83PubMedCrossRefGoogle Scholar
  31. 31.
    Fennerty MB, Johanson J, Hwang C, et al. Esomeprazole 40mg versus lansoprazole 30mg in healing and symptomatic relief in patients with moderate to severe erosive esophagitis (Los Angeles Grades C or D). Aliment Pharmacol Ther 2005; 21(4): 455–63PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson DA, Hoyle PE, Traxler BM, et al. An evidence-based approach provides a quantitative assessment of the efficacy of esomeprazole for healing of erosive esophagitis based on disease severity [abstract]. Am J Gastroenterol 2003; 98: S16Google Scholar
  33. 33.
    Vieth M, Kulig M, Leodolter A, et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal esophagus. Alim Pharmacol Ther 2006; 23: 313–9CrossRefGoogle Scholar
  34. 34.
    Pilotto A, Franceschi M, Leandro G, et al. Comparison of four proton pump inhibitors for short term treatment of esophagitis in elderly patients. World J Gastroenterol 2007 Sep 7; 13(33): 4467–72PubMedGoogle Scholar
  35. 35.
    Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; (2): CD003245Google Scholar
  36. 36.
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12PubMedGoogle Scholar
  37. 37.
    Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27–34PubMedCrossRefGoogle Scholar
  38. 38.
    Klok RM, Postma MJ, van Hout BA, et al. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003; 17: 1237–45PubMedCrossRefGoogle Scholar
  39. 39.
    Kaspari S, Kupcinskas L, Heinze H, et al. Pantoprazole 20mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005; 17: 935–41PubMedCrossRefGoogle Scholar
  40. 40.
    Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002; 37: 642–7PubMedCrossRefGoogle Scholar
  41. 41.
    Sjostedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 183–91PubMedCrossRefGoogle Scholar
  42. 42.
    Dean BB, Gano Jr AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656–64PubMedCrossRefGoogle Scholar
  43. 43.
    Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal esophagitis. Aliment Pharmacol Ther 1996; 10: 547–55PubMedCrossRefGoogle Scholar
  44. 44.
    Richter JE, Kovacs TOG, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 1996; 13: 795–804CrossRefGoogle Scholar
  45. 45.
    Chey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD, a double blind, randomised, multicenter trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23(2): 69–84CrossRefGoogle Scholar
  46. 46.
    Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999; 45: 1131–6CrossRefGoogle Scholar
  47. 47.
    Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms a double blind randomized trial. Clin Gastroenterol Hepatol 2006; 4: 50–6PubMedCrossRefGoogle Scholar
  48. 48.
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974–9PubMedCrossRefGoogle Scholar
  49. 49.
    Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810–6PubMedCrossRefGoogle Scholar
  50. 50.
    Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885–92PubMedCrossRefGoogle Scholar
  51. 51.
    Richter JE, Zuccaro G. Esophageal diseases. In: Classen M, Tytgat GNJ, Lightdale CJ, editors. Gastroenterological Endoscopy. Stuttgart: Thieme Publishers, 2002: 452–65Google Scholar
  52. 52.
    Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487–93PubMedCrossRefGoogle Scholar
  53. 53.
    Fass R, Traxler BM, Thomas S, et al. Once daily esomeprazole and twice daily lansoprazole for nocturnal heartburn in patients with GERD [abstract]. Am J Gastroenterol 2003; 98: S36Google Scholar
  54. 54.
    Castell DO. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother 2005; 6: 2501–10PubMedCrossRefGoogle Scholar
  55. 55.
    Castell D, Bagin R, Goldlust B, et al. Comparison of the effects of immediate release omeprazole powder for oral suspension and pantoprazole delayed release tablets on nocturnal acid breakthrough in patients with symptomatic gastroesophageal reflux. Aliment Pharmacol Ther 2005; 21: 1467–74PubMedCrossRefGoogle Scholar
  56. 56.
    Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907–15PubMedGoogle Scholar
  57. 57.
    Swarbrick ET, Gough AL, Foster CS, et al. Prevention of recurrence of oesophageal stricture: a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996; 8: 431–8PubMedGoogle Scholar
  58. 58.
    Triadafilopoulos G. Acid and bile reflux in Barrett’s esophagus: a tale of two evils. Gastroenterology 2001; 121: 1502–6PubMedCrossRefGoogle Scholar
  59. 59.
    Triadafilopoulos G. Management of Barrett’s esophagus with and without dysplasia. Scand J Gastroenterol Suppl 2003; 237: 40–6PubMedCrossRefGoogle Scholar
  60. 60.
    Fitzgerald RC, Lascar R, Triadafilopoulos G. Barrett’s oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001; 15: 269–76PubMedCrossRefGoogle Scholar
  61. 61.
    El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2004; 99: 1877–83PubMedCrossRefGoogle Scholar
  62. 62.
    Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barret’s esophagus. Med J Aust 2004; 180: 387–91PubMedGoogle Scholar
  63. 63.
    Yeh RW, Triadafilopoulos G. Endoscopic therapy for Barrett’s esophagus. Gastrointest Endosc Clin N Am 2005; 15: 377–97PubMedCrossRefGoogle Scholar
  64. 64.
    Yeh RW, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus 2003; 16: 193–8PubMedCrossRefGoogle Scholar
  65. 65.
    Hewson EG, Sinclair JW, Dalton CB, et al. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating non-cardiac chest pain. Am J Med 1991; 90: 576–83PubMedGoogle Scholar
  66. 66.
    Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with ‘reflux laryngitis’. Gastroenterology 1991; 100: 305–10PubMedGoogle Scholar
  67. 67.
    Shaker R, Milbrath M, Ren J, et al. Esophago-pharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995; 109: 1575–82PubMedCrossRefGoogle Scholar
  68. 68.
    Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med 1994; 96: 321–6PubMedCrossRefGoogle Scholar
  69. 69.
    Vaezi M, Richter J, Stasney R, et al. A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngo-pharyngeal reflux. Laryngoscope 2006; 116: 254–60PubMedCrossRefGoogle Scholar
  70. 70.
    Howden CW, Leontiadis GI, Sharma VK. Randomized controlled trials comparing PPI with placebo in reflux laryngitis: a systematic review [abstract]. Gastroenterology 2004; 126: A99CrossRefGoogle Scholar
  71. 71.
    Richter JE. Ear, nose and throat and respiratory manifestation of gastro-esophageal reflux disease: an increasing conundrum. Eur J Gastroenterology Hepatology 2004; 16: 837–45CrossRefGoogle Scholar
  72. 72.
    Kushner JP, Steward DL. Effect of pantoprazole on typical and atypical reflux symptoms in a prospective cohort of patients with obstructive sleep disordered breathing [abstract]. Am J Gastroenterol 2004; 99: S7CrossRefGoogle Scholar
  73. 73.
    Schoeffel L, Naumburger A, Gillessen A, et al. Superiority of pantoprazole 40mg versus omeprazole 20mg in relieving GERD-associated sleep disturbances [abstract]. Am J Gastroenterol 2004; 99: S237Google Scholar
  74. 74.
    Contini S, Scarpignato C. Endoscopie treatment of gastro-oesophageal reflux disease (GORD): a systematic review. Dig Liver Dis 2003; 35: 818–38PubMedCrossRefGoogle Scholar
  75. 75.
    Lundell L, Mietinnen P, Myrvold HE, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastro-esophageal reflux disease. J Am Coll Surg 2001; 192: 172–9PubMedCrossRefGoogle Scholar
  76. 76.
    Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastro-esophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8PubMedCrossRefGoogle Scholar
  77. 77.
    Richards WO, Houston HL, Torquati A, et al. Paradigm shift in the management of gastro-esophageal reflux disease. Ann Surg 2003; 237: 638–47PubMedGoogle Scholar
  78. 78.
    Chadalavada R, Lin E, Swafford V, et al. Comparative results of endoluminal gastroplasty and laparoscopic antireflux surgery for the treatment of GERD. Surg Endosc 2004; 18: 261–5PubMedCrossRefGoogle Scholar
  79. 79.
    Holt S, Howden CW. Omeprazole. overview and opinion. Dig Dis Sci 1991; 36: 385–93Google Scholar
  80. 80.
    Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661–5PubMedGoogle Scholar
  81. 81.
    Dekkers CP, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179–86PubMedCrossRefGoogle Scholar
  82. 82.
    Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8 Suppl. 1: 47–52Google Scholar
  83. 83.
    Lin HJ, Lo WC, Cheng YC, et al. Effects of 3 day IV pantoprazole vs omeprazole on 24hr intragastric acidity at 3 days in Chinese patients with duodenal ulcer: a single center prospective randomized, comparative, pilot trial. Clin Ther 2006; 9: 1303–7CrossRefGoogle Scholar
  84. 84.
    Peura DA. Prevention of non-steroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117 Suppl. 5A: 63–71SGoogle Scholar
  85. 85.
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037–46Google Scholar
  86. 86.
    Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–26Google Scholar
  87. 87.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–34Google Scholar
  88. 88.
    Bianchi Porro G, Lazzaroni M, Manzionna G, et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998 Apr; 12(4): 355–60PubMedCrossRefGoogle Scholar
  89. 89.
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321(7270): 1183–7PubMedCrossRefGoogle Scholar
  90. 90.
    Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44PubMedCrossRefGoogle Scholar
  91. 91.
    Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967–73PubMedCrossRefGoogle Scholar
  92. 92.
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–8PubMedCrossRefGoogle Scholar
  93. 93.
    Goldstein JL, Miner Jr PD, Schlesinger PK, et al. Intra-gastric acid control in nonsteroidal antiinflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006; 23: 1189–26PubMedCrossRefGoogle Scholar
  94. 94.
    Hawkey C, Talley NJ, Yeomans ND, et al. Improvement with esomeprazole in patients with upper gstrointestinal symptoms taking NSAIDS including selective cox-2 inhibitors. Am J Gastroenterol 2005; 100: 1028–36PubMedCrossRefGoogle Scholar
  95. 95.
    Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59: 1210–7PubMedCrossRefGoogle Scholar
  96. 96.
    Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135–40PubMedCrossRefGoogle Scholar
  97. 97.
    Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multi-centre study. Scand J Gastroenterol 1996; 31: 753–8PubMedCrossRefGoogle Scholar
  98. 98.
    Scheinman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NS AIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701–10CrossRefGoogle Scholar
  99. 99.
    Graham DY, Agrawal NM, Campbell DR, et al., for the NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double-blind, randomized, multi-center, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169–75PubMedCrossRefGoogle Scholar
  100. 100.
    Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650–7PubMedCrossRefGoogle Scholar
  101. 101.
    Kositchaiwat C, Ovartlarnporn B, Kachintorn U, et al. Low and high doses of rabeprazole vs omeprazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 1017–21PubMedCrossRefGoogle Scholar
  102. 102.
    Bazzoli F, Bianchi Porro G, et al. Treatment of Helicobacter pylori infection: indications and regimens: an update. Dig Liver Dis 2002; 34: 70–83PubMedCrossRefGoogle Scholar
  103. 103.
    Hsu PI, Laik H, Lin CK, et al. Prospective randomised trial of esomeprazole vs pantoprazole based triple therapy for H. pylori eradication. Am J of Gastroenterol 2005; 100: 2387–92CrossRefGoogle Scholar
  104. 104.
    Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238–46PubMedCrossRefGoogle Scholar
  105. 105.
    Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–2PubMedCrossRefGoogle Scholar
  106. 106.
    Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006–12PubMedCrossRefGoogle Scholar
  107. 107.
    Kupfer Y, Cappell MS, Tessler S. Acute gastrointestinal bleeding in the intensive care unit: the intensivist’s perspective. Gastroenterol Clin North Am 2000; 29: 275–307PubMedCrossRefGoogle Scholar
  108. 108.
    Cook DJ, Guyatt GH, Salena BJ, et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102: 139–48PubMedGoogle Scholar
  109. 109.
    Savides TJ, Jensen DM. Therapeutic endoscopy for nonvariceal gastrointestinal bleeding. Gastroenterol Clin North Am 2000; 29: 465–87PubMedCrossRefGoogle Scholar
  110. 110.
    Yilmaz S, Bayun K, Dursun M, et al. Does adding misoprostol to standard IV PPI protocol improve the outcome of aspirin/ NSAID-induced upper GI bleeding? A randomised prospective study. Dig Dis Sci 2007; 52: 110–8PubMedCrossRefGoogle Scholar
  111. 111.
    Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38–43PubMedGoogle Scholar
  112. 112.
    Berstad A, Holm HA, Kittang E. Experience with antipeptic agents. Scand J Gastroenterol (Suppl) 1979; 55: 121–3Google Scholar
  113. 113.
    Berstad A. Antacids, pepsin inhibitors, and gastric cooling in the management of massive upper gastrointestinal haemorrhage. Scand J Gastroenterol (Suppl) 1987; 137: 33–8CrossRefGoogle Scholar
  114. 114.
    Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568PubMedCrossRefGoogle Scholar
  115. 115.
    Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. J Surg 2007; 77: 677–81Google Scholar
  116. 116.
    Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007: 356:1631–40PubMedCrossRefGoogle Scholar
  117. 117.
    Lau JY, Sung JJ, Lee KKC, et al. Effect of IV omeprazole on recurrent bleeding after endoscopie treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310–6PubMedCrossRefGoogle Scholar
  118. 118.
    Bajaj JS, Dra KS, Hanson K, et al. Prospective randomized trial comparing effect of oral versus intravenous pantoprazole on re-bleeding after non-variceal upper gastrointestinal study a pilot study. Dig Dis Sci 2007; 52: 2190–4PubMedCrossRefGoogle Scholar
  119. 119.
    Jensen DM. Spots and clots: leave them or treat them? Why and how to treat. Can J Gastroenterol 1999; 13: 413–5PubMedGoogle Scholar
  120. 120.
    Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: 211–6PubMedCrossRefGoogle Scholar
  121. 121.
    Leontiadis G, McIntyre L, Sharma V, et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004; (3): CD002094Google Scholar
  122. 122.
    Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200–9PubMedCrossRefGoogle Scholar
  123. 123.
    Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498–508PubMedGoogle Scholar
  124. 124.
    Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia: best evidence synthesis. Scand J Gastroenterol (Suppl) 1995; 210: 48–52CrossRefGoogle Scholar
  125. 125.
    Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377–81PubMedCrossRefGoogle Scholar
  126. 126.
    Ben-Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. Ann Intern Med 1994; 121: 568–75PubMedGoogle Scholar
  127. 127.
    Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987; 106: 562–7PubMedGoogle Scholar
  128. 128.
    Maton PN. Prevention of stress-related mucosal bleeding with proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 Suppl. 3: 45–52CrossRefGoogle Scholar
  129. 129.
    Kantorova I, Svoboda P, Scheer P, et al Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepato-gastroenterology 2004; 51(57): 757–61PubMedGoogle Scholar
  130. 130.
    Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997; 42: 1255–9PubMedCrossRefGoogle Scholar
  131. 131.
    Phillips JO, Metzler MH, Palmieri MT, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793–800PubMedCrossRefGoogle Scholar
  132. 132.
    Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically-significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44: 527–33PubMedCrossRefGoogle Scholar
  133. 133.
    Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother 2003; 37: 631–5PubMedCrossRefGoogle Scholar
  134. 134.
    Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 Suppl. 2: II37–43PubMedCrossRefGoogle Scholar
  135. 135.
    Talley NJ, Zinmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259–68PubMedGoogle Scholar
  136. 136.
    Karamanolis G, Caenepeel P, Arts J, et al. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130: 296–303PubMedCrossRefGoogle Scholar
  137. 137.
    Thomson A, Barkun A, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric treatment-prompt endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481–91PubMedCrossRefGoogle Scholar
  138. 138.
    Sreedharan A, Clough M, Hemingbrough E, et al. Cost-effectiveness and long-term impact of Helicobacter pylori ‘test and treat’ service in reducing open access endoscopy referrals. Eur J Gastroenterol Hepatol 2004; 16: 981–6PubMedCrossRefGoogle Scholar
  139. 139.
    Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori [abstract]. CMAJ 2000; 162 (12 Suppl.): S3PubMedGoogle Scholar
  140. 140.
    Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006; 119(448): e27–36PubMedGoogle Scholar
  141. 141.
    Chey WD, Lukasik N, Huang B, et al. Lansoprazole effectively reduces the risk of GI symptom occurrence in ulcer free patients who continue chronic NSAID use [abstract]. Am J Gastroenterol 2003; 98: S296Google Scholar
  142. 142.
    Meineche-Schmidt V. Classification of dyspepsia and response to treatment with proton-pump inhibitors. Aliment Pharmacol Ther 2004; 20: 1171–9PubMedCrossRefGoogle Scholar
  143. 143.
    Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag 2000; 7: 29–34Google Scholar
  144. 144.
    Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 709–14PubMedCrossRefGoogle Scholar
  145. 145.
    Katz PO, Anderson C, Khoury R, et al. Gastroesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231–4PubMedCrossRefGoogle Scholar
  146. 146.
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9–28PubMedCrossRefGoogle Scholar
  147. 147.
    Park S, Lee S, Song K, et al. The pharmacological properties of a novel acid pump antagonist, YH1885 [abstract]. Gut 2003; 52: A9Google Scholar

Copyright information

© adis data information BV 2008

Authors and Affiliations

  • Vandana Boparai
    • 1
  • Jaishree Rajagopalan
    • 1
  • George Triadafilopoulos
    • 1
  1. 1.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA

Personalised recommendations